These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20589314)

  • 1. Comparison of plasma-derived and recombinant von Willebrand factor by atomic force microscopy.
    Seyfried BK; Friedbacher G; Rottensteiner H; Schwarz HP; Ehrlich H; Allmaier G; Turecek PL
    Thromb Haemost; 2010 Sep; 104(3):523-30. PubMed ID: 20589314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
    Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
    Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of a recombinant von Willebrand factor drug candidate.
    Turecek PL; Schrenk G; Rottensteiner H; Varadi K; Bevers E; Lenting P; Ilk N; Sleytr UB; Ehrlich HJ; Schwarz HP
    Semin Thromb Hemost; 2010 Jul; 36(5):510-21. PubMed ID: 20635317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease.
    Gritsch H; Schrenk G; Weinhappl N; Mellgård B; Ewenstein B; Turecek PL
    J Blood Med; 2022; 13():649-662. PubMed ID: 36405429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a plasma- and albumin-free recombinant von Willebrand factor.
    Turecek PL; Mitterer A; Matthiessen HP; Gritsch H; Varadi K; Siekmann J; Schnecker K; Plaimauer B; Kaliwoda M; Purtscher M; Woehrer W; Mundt W; Muchitsch EM; Suiter T; Ewenstein B; Ehrlich HJ; Schwarz HP
    Hamostaseologie; 2009 Oct; 29 Suppl 1():S32-8. PubMed ID: 19763356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
    Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
    Haemophilia; 1998; 4 Suppl 3():53-62. PubMed ID: 10028320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of nano-electrospray gas-phase electrophoretic mobility macromolecular analysis and matrix-assisted laser desorption/ionization linear time-of-flight mass spectrometry for the characterization of the recombinant coagulation glycoprotein von Willebrand factor.
    Kemptner J; Marchetti-Deschmann M; Müller R; Ivens A; Turecek P; Schwarz HP; Allmaier G
    Rapid Commun Mass Spectrom; 2010 Mar; 24(6):761-7. PubMed ID: 20169558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.
    Turecek PL; Gritsch H; Pichler L; Auer W; Fischer B; Mitterer A; Mundt W; Schlokat U; Dorner F; Brinkman HJ; van Mourik JA; Schwarz HP
    Blood; 1997 Nov; 90(9):3555-67. PubMed ID: 9345039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease.
    Hommais A; Stépanian A; Fressinaud E; Mazurier C; Pouymayou K; Meyer D; Girma JP; Ribba AS
    Thromb Haemost; 2006 May; 95(5):776-81. PubMed ID: 16676067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products.
    Turecek PL; Ilk R; Gritsch H
    Haemophilia; 2024 Jan; 30(1):151-160. PubMed ID: 37926687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
    Bauer A; Friberg-Hietala S; Smania G; Wolfsegger M
    J Blood Med; 2023; 14():399-411. PubMed ID: 37332615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-molecule force measurements of the polymerizing dimeric subunit of von Willebrand factor.
    Wijeratne SS; Li J; Yeh HC; Nolasco L; Zhou Z; Bergeron A; Frey EW; Moake JL; Dong JF; Kiang CH
    Phys Rev E; 2016 Jan; 93(1):012410. PubMed ID: 26871104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability.
    Muchitsch EM; Dietrich B; Rottensteiner H; Auer W; Nehrbass D; Gritsch H; Ehrlich HJ; Turecek PL; Schwarz HP
    Semin Thromb Hemost; 2010 Jul; 36(5):522-8. PubMed ID: 20632249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
    Mannucci PM; Kempton C; Millar C; Romond E; Shapiro A; Birschmann I; Ragni MV; Gill JC; Yee TT; Klamroth R; Wong WY; Chapman M; Engl W; Turecek PL; Suiter TM; Ewenstein BM;
    Blood; 2013 Aug; 122(5):648-57. PubMed ID: 23777763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of human von Willebrand factor with a hydrophobic self-assembled monolayer studied by atomic force microscopy.
    Siedlecki CA; Eppell SJ; Marchant RE
    J Biomed Mater Res; 1994 Sep; 28(9):971-80. PubMed ID: 7814438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.
    Siedlecki CA; Lestini BJ; Kottke-Marchant KK; Eppell SJ; Wilson DL; Marchant RE
    Blood; 1996 Oct; 88(8):2939-50. PubMed ID: 8874190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
    Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D
    Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New assay for measuring binding of platelet glycoprotein IIb/IIIa to unpurified von Willebrand factor.
    Veyradier A; Jumilly AL; Ribba AS; Obert B; Houllier A; Meyer D; Girma JP
    Thromb Haemost; 1999 Jul; 82(1):134-9. PubMed ID: 10456467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.